Eledon Pharmaceuticals Inc (ELDN)
Eledon Pharmaceuticals Inc. is a clinical-stage biotechnology company listed on NASDAQ under the ticker ELDN. The company focuses on immunology-based research and development, with an emphasis on therapies that act on the CD40L pathway. Its development programs include tegoprubart, an antibody candidate being studied for applications in organ transplantation, transplant rejection, and amyotrophic lateral sclerosis (ALS). Eledon is also pursuing work related to kidney allograft rejection and xenotransplantation. The company has collaboration agreements with eGenesis, Inc. and NewcelX Ltd., including development activity for NCEL-101 in Type 1 diabetes. Eledon Pharmaceuticals is headquartered in Irvine, California, and was previously known as Novus Therapeutics, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ELDN
|
$3.59
|
-9.7% Downside
|
Fair
|
$9
|
126.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-4.0x
|
3.1x
|
—
|
298.4 M
|
198.3 M
|
0.2%
|
90.6%
|
-3.0
|
—
|
88.2%
|
